Insider selling
Traded Oct 22, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
A Quest Diagnostics director sold $270K of Quest Diagnostics shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 26, 2025 · Filed Sep 30, 2025
Quest Diagnostics's SVP & General Counsel sold $16K of Quest Diagnostics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$15,539
Shares × reported transaction price
66 days after results of Jul 22, 2025, 25 days before results of Oct 21, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $188.99 on Sep 26, 2025, at its 52-week high, after a 6% rise over the previous 30 trading days
52-week range $146.90 (Oct 7, 2024) to $188.99 (Sep 26, 2025), 100% of the way up, from 247 adjusted closes. 30 trading days earlier: $178.44 on Aug 14, 2025. Describes the past only, not a forecast
RSI 66, 11% above its 200-day average, 6% above its 50-day average, at the 52-week high, 20-day volatility 17% a year, against the S&P 500: +3 points over 1 month, −1 points over 3 months, −3 points over 6 months
From the adjusted closes up to Sep 26, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −0.7% | +0.7% | −1.4% |
| 30 days | −3.4% | +2.0% | −5.4% |
| 90 days | −3.6% | +2.8% | −6.4% |
| 180 days | +8.3% | −5.5% | +13.8% |
| 365 days | +26.9% | +14.3% | +12.6% |
Past results only. Not a forecast.
Insider selling
Traded Oct 22, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
A Quest Diagnostics director sold $270K of Quest Diagnostics shares. The filing does not indicate a pre-arranged trading plan.
Fund moves
43 tracked managers disclosed the same change for Q3 2025. From a 13F filed Oct 17, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
10 tracked managers disclosed the same change for Q3 2025. From a 13F filed Oct 10, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.